Reporting is learning. By reporting data on patients treated with CAR T-cell therapies, you contribute to academic research and regulatory decision making by health authorities. Ultimately, this supports EBMT’s mission to advance cellular and stem-cell based therapies and improve the lives of patients with blood-related disorders.
Data quality is fundamental to doing meaningful analyses. To ensure that we have complete and accurate data, EBMT invites centres that treat patients with commercial CAR T-cell therapies to participate in a Data Collection Initiative to support Post Authorisation Safety (PAS) studies mandated by the European Medicines Agency (EMA). Centres that participate will be financially compensated.
How is the Data Collection Initiative set up to support PAS studies?
The data collection for PAS studies is based on the standard Registry forms and procedures, but a wider infrastructure is being set-up to support PAS studies and reimburse centres for their work.
Informed Consent Form
The adapted EBMT consent form allows patient level data to be shared with MAHs and the EMA, for the sole purpose of supporting PAS studies and ultimately, regulatory decision making.
To participate in a Data Collection Initiative, a centre must sign the Data Collection Master Agreement and a Product Specific Agreement. In addition, all EBMT centres should have a Joint Controllership Agreement in place.
Report data on all patients treated with CAR-T therapy within six weeks of treatment or any follow-up visits.
With the approval of the first CAR-T therapies, the EMA required MAHs to monitor their products in the long-term. The cellular therapy module of the EBMT Registry received a positive qualification opinion from the EMA, supporting the use of Real-World Data captured in the EBMT Registry to inform regulatory decision making by health authorities.
Frequently Asked Questions (FAQs)
What are the requirements for participation in the Data Collection Initiative?
- To participate in the Data Collection Initiative on CAR-T therapies, a centre must, first and foremost, report data on all patients treated with (commercial) CAR-T therapies in the EBMT Registry as per the standard data collection forms and processes (the Cellular Therapy form). This does not require any additional contracts and/or regulatory approvals. Consequently, this data collection is already ongoing and should continue.
- Secondly, if needed, help the EBMT Clinical Study Unit with obtaining regulatory approval for the updated informed consent form which allows patients to also consent to share the data collected in the Registry with EBMT’s collaboration partners including MAHs and health authorities.
- Thirdly, (re-)consent patients with the updated informed consent form.
- Finally, help to set up contracts between your centre and EBMT which allows EBMT to reimburse your site for the data management efforts. (See the question “What contracts should my centre sign?” below).
What does my centre have to do when participating in the Data Collection Initiative?
- You will need to complete the standard patient data in the EBMT Registry from August 24 onwards. In addition, we ask you to comply with data requests (queries) to ensure completeness and quality of the data.
- Data on patients treated with CAR-T therapies needs to be reported at the following time points: baseline, 100 days, 6 months and then yearly up until 15 years have passed and at that time a 15-year follow-up will be conducted.
- Also, we ask you to consent patients with the updated patient informed consent form, which asks patients to indicate whether they allow sharing of their data with EBMT collaboration partners and source data verification of their data.
- ly patients who explicitly consent to share their data with collaboration partners will be included in the dataset that is shared with these parties. The centre should also be available for on-site monitoring visits.
Why should my centre participate? What is in it for me?
- Participation in the Data Collection Initiative is important because ‘reporting is learning’. The PAS studies are mandated by EMA because we lack information on the long-term safety and efficacy profiles of CAR-T therapies. As a prominent European medical community, we want to be in the lead of evidence generation of these promising treatments. Collectively we can generate robust real-world evidence to support regulatory decision making as well as scientific studies.
- The current protocols for the PAS studies are based on secondary use of Registry data. With this approach we prevent the creation of additional databases owned by marketing authorisation holders. The EBMT Registry makes data available to the scientific community and it avoids the need for centres to report data to multiple registries. By using a harmonised data collection form for cellular therapies, it will be easier to enter and compare data on different products.
- Centres will receive a generous reimbursement for their data management efforts. This money will be given for all patients treated with commercial CAR-T therapies who (re-)consent to sharing their pseudonymised data with MAHs as per the Product -Specific Agreement between the participating site and EBMT.
- If you have a good study proposal for a CAR-T-related study, you can submit it to the relevant EBMT Working Parties or the GoCART Coalition. When your proposal is selected/accepted, you will not only have access to the data from your centre but (indirectly) also to data from other centres in your country or the Registry as a whole. Working Parties have dedicated statisticians, data managers and study coordinators to support the conduct of the selected proposals.
What contracts should my centre sign?
- The contracts for the Data Collection Initiative for the PAS studies are split in two parts; the Data Collection Master Agreement and the Product- Specific Agreement. The Data Collection Master Agreement governs the general data collection requirements that are identical for all CAR-T therapies. Whereas the shorter Product Specific Agreement specifies additional requirements for the individual CAR-T therapies. For each new product you will only need to sign a new Product-Specific Agreement.
- By using this set-up, in which the Product-Specific Agreements are incorporated in the Data Collection Master agreement, we aim to reduce the time needed for contract negotiations and thus reduce the start-up timelines and burden for new cellular therapy products included in the Data Collection Initiative.
- We also remind your centre to sign the Joint Controllership Agreement (JCA). This document governs all data processing activities between EBMT and the centre and is thus a prerequisite but not specific to participate in the CAR-T Data Collection Initiative. The JCA should be signed by all centres, including those who do not participate in the CAR-T Data Collection Initiative.
Will my centre be reimbursed?
- If your centre has agreed to participate in the Data Collection Initiative and has signed the relevant contracts, your centre will be reimbursed for all patients treated with commercial CAR-T therapy products that (re-)consent to allow sharing of their data with the marketing authorisation holders and health authorities as per the stipulations in the Product-Specific Agreement. You will only be reimbursed for patients treated after the marketing approval date in the post-marketing setting and when good quality data is entered and can be shared with the MAHs. The specific details of the inclusion period and payment schedule is provided in each Product-Specific Agreement. In addition to the Agreements, EBMT will inform the sites which indications are contracted with the pharma company to get paid for those patients. When a new indication is contracted with the pharma company EBMT will inform the sites accordingly. In summary:
- For Kymriah® this means until the inclusion target of 2500 patients globally has been reached (competitive enrollment). On 24 April 2023, the inclusion was closed for this product. Any patients included after this date will not be reimbursed. The marketing approval date for Kymriah® is 23-Aug-2018 and the currently contracted indications are: pediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse; and for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
- For Yescarta® this means all patients treated till 23 May 2025, unless the inclusion period is closed earlier per EBMT notification. The marketing approval date for Yescarta® is 23-Aug-2018 and the currently contracted indications are: adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL).
- For Abecma® this means until the inclusion target of 300 patients in Europe has been reached (competitive enrollment). The marketing approval date for Abecma® is 18-Aug-2021 and the currently contracted indications are: adult patients with multiple myeloma.
- For Breyanzi® this means until the inclusion target of 200 patients in Europe has been reached (competitive enrollment). The marketing approval date for Breyanzi® is 04-Apr-2022 and the currently contracted indications are: adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B).
- For Tecartus® this means all patients treated until 18 Jan 2028, unless the inclusion period is closed earlier per EBMT notification. The marketing approval date for Tecartus® is 14-Dec-2022 and the currently contracted indications are: adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).
- More products and/or additional indications are expected to follow in the near future.
Find your country. Find your contact.
EBMT has appointed both lead study coordinators and lead investigators for each country. Please refer to the list below to identify the contact person in your country.
|Country||Lead EBMT||Country lead PI|
|Austria||Guus Rijs||Philipp Wohlfarth, MD, PhD; Medical University of Vienna, Vienna|
|Belgium||Guus Rijs||Sébastien Anguille, MD, PhD; Antwerp University Hospital/University of Antwerp, Antwerp|
|Croatia||Paul Bosman||Prof. Igor Aurer - University Hospital Center Rebro|
|Czech Republic||Paul Bosman||Frantisek Folber, MD, PhD - Department of Internal Medicine, Hematology and Oncology, University Hospital Brno|
|Denmark||Guus Rijs||Soeren Lykke Petersen, Consultant, MD, D. Msc. - Copenhagen University Hospital (Rigshospitalet)|
|Finland||Dilyana Georgieva||Dr. Mervi Taskinen MD, PhD - University of Helsinki, Helsinki|
|France||Jessica Lemaitre||Pr Stéphanie Nguyen -Universite Paris IV, Hopital la Pitié-Salpêtrière, Paris|
|Germany||George Haroon||Prof. Dr. med. Nicolaus Kröger - University Hospital Eppendorf, Hamburg|
|Israel||Paul Bosman||Prof. Avichai Shimoni - Chaim Sheba Medical Center|
|Italy||Paul Bosman||Dr. Annalisa Ruggeri MD, PhD - Ospedale San Raffaele s.r.l|
|Netherlands||Guus Rijs||Dr. Pim Mutsaers van het Erasmus Medical Center, Rotterdam|
Tobias Gedde-Dahl d.y. MD PhD - Oslo University Hospital Rikshospitalet, Oslo
|Poland||Paul Bosman||Prof. Krzysztof Kalwak - Cape of Hope, Wroclaw|
|Slovenia||Paul Bosman||Dr. Matjaz Sever MD, PhD - University Medical Center Ljubljana|
|Spain||Paul Bosman||Dr. Anna Sureda MD, PhD- ICO- Hospital Duran i Reynals, Barcelona|
|Sweden||Dilyana Georgieva||Prof. Dr. Stephan Mielke - Karolinska University Hospital, Stockholm|
Prof. Dr. med. Caroline Arber Barth - université de Lausanne, Centre hospitalier universitaire vaudois, Lausanne
|United Kingdom||Dilyana Georgieva||
Dr. Sara Ghorashian, Great Ormond Street Hospital, London
Contact us if your country is not listed at EBMT_NK01@lumc.nl
CAR T-cell treated patients registered in the EBMT Registry
EBMT is a Non-Profit Organisation
EBMT is a non-profit organization supporting the transplant and cellular therapy community. In line with our Mission, Vision and Values, our resources are used to improve the lives of patients with blood-related disorders.
EBMT has created a level of financial reserves to be able to guarantee its independence and neutrality regarding all its scientific and educational decisions from any political and economic interest. All income to EBMT is re-invested to support our community with it scientific, registry, accreditation and educational activities.
Recent activities and outputs in CAR T include: International Training Course, GoCART Consortium, EBMT-JACIE/EHA CAR T Guidelines, EBMT-EHA CAR T Handbook and the CAR T Data Registry amongst others.
For more information about EBMT's involvement in the PAS Studies please visit the FAQs page.